Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

TRULICITY® (dulaglutide): Gastroparesis

Trulicity (dulaglutide) has not been studied in patients with severe or preexisting gastroparesis.

US_cFAQ_GLP011_GASTROPARESIS
US_cFAQ_GLP011_GASTROPARESIS
en-US

Detailed Information

Dulaglutide slows gastric emptying.1

The use of dulaglutide may be associated with GI adverse reactions, sometimes severe.1

Dulaglutide has not been studied in patients with severe GI disease, including severe or preexisting gastroparesis, and is therefore not recommended in these patients.1

Reference

1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Glossary

GI = gastrointestinal

Date of Last Review: May 11, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical